SinuShunt - development of
an improved hydrocephalus shunt
CSF-Dynamics has developed a new type of hydrocephalus shunt that overcomes the major issues of standard of care shunts by offering a new physiological drainage method. Our pilot study was funded by a Horizon 2020 Phase 2 SME grant (849502) from the European Innovation Council and we are now planning a larger study in 3 European countries. CSF-Dynamics expects the shunt to be approved for clinical use by 2030.
Please contact us by email if you are interested to know more about the technology and the status of the development or if you would like to partner with us.
Hydrocephalus Day 2025
For World Hydrocephalus Day 2025 we are focusing on Normal Pressure Hydrocephalus, the form of the condition which affects 3.7% of patients aged 65 and over and 8.9% of patients over 80.
​​
It is widely recognised that this type of hydrocephalus is underdiagnosed and the standard treatment can be ineffective (see NPH below). This is likely to cause a crisis in many European countries in the coming years as the population ages and patients will either miss out on treatment (through lack of awareness or misdiagnoses) or will suffer from inadequate treatment due to device failure.
We are currently seeking investment to support a pivotal study to validate our new SinuShunt system to prove the device can offer long term hydrocephalus treatment in time for this paradigm shift.
Normal Pressure Hydrocephalus (NPH)
Fact Sheet
-
Hydrocephalus, also known as water on the brain, is a condition where cerebrospinal fluid accumulates and causes increased pressure on the brain. It can be acute, or chronic.
-
40% of all hydrocephalus sufferers are affected by the chronic form. These patients are usually in the age group over 65
-
The chronic form is also known as Normal Pressure Hydrocephalus (NPH). Symptoms are unsteadiness/difficulty in walking, urinary incontinence and dementia (some US patient groups refer to it as “wobbly, wet and wacky”)
-
NPH is severely underdiagnosed, with a prevalence of 3.7% over the age of 65 and 8.9% over 80 suffering from the condition.
-
NPH and therefore this form of dementia is treatable with a shunt (the only kind of dementia which can be treated in this way)
-
The condition is catastrophically underdiagnosed with only a fraction of patients being referred because the symptoms are confused with general ageing or with Alzheimer’s
-
Current shunts and shunting methods have a failure rate of up to 40% within 6 months.
We are currently planning a multi-centre clinical study led by Odense University Hospital to investigate our novel SinuShunt which offers a superior solution to serve these NPH patients. We hope to have market approval for our device shortly after the study has ended.
Clinical results:
JNS article
After several years of research and technological development at CSF-Dynamics we can now present the results of the pilot study on our novel CSF-shunting device. This method of shunting to the intracranial sinus for the treatment of hydrocephalus is intended to significantly reduce both revisions and complications by mimicking physiological drainage. We would like to thank Dr Sune Munthe and his team at Odense University Hospital for supporting us in this investigation and showing that our shunt remains patent and avoids overdrainage. We are convinced that this method has a future in the standard of care and will move forwards to plan a larger international study as soon as possible.
​
The abstract can be found on the Journal of Neurosurgery.
NEWS: Follow us on LinkedIn
